Artificial Intelligence will be a critical component in ensuring a Europe-wide lung cancer screening programme can achieve its potential, according to speakers at a special ECR 2024 session. Delegates heard that the SOLACE project (Strengthening the screening of Lung Cancer in Europe) will be supported by AI in terms of workflow, diagnostics, and image and data analysis.
Finnish researchers found that using a mobile application based on cognitive behavioral therapy can significantly boost success rates of people attempting to stop smoking.
Lung cancer screenings save lives – especially for those who live in economically deprived areas, a new study confirms. The researchers further demonstrate the benefits of using low-dose CT imaging.
When it comes to lung cancer care, patients in Europe face significant differences depending on the country they are in. Researchers from Amsterdam analysed the landscape.
Under certain circumstances, lung tumours can transform into another, more aggressive cancer type. Now, researchers have found a way to illuminate this process, known as histological transformation.
Using a new technology developed at MIT, diagnosing lung cancer could become as easy as inhaling nanoparticle sensors and then taking a urine test that reveals whether a tumor is present.
Incidence of lung cancer among people who never smoked is rising. A new AI tool opens the door for opportunistic screening for this group, using existing chest X-rays in the electronic medical record.
AI features for automation, integrated systems and more: the role of medical technology has never been as vital as today, and MedTech companies from Taiwan are putting their best foot forward to contribute. At the 2023 Medica trade fair, visitors of the Taiwanese pavilion not only had the opportunity to see the latest medical products on display, but also get acquainted with Taiwanese culture in…
Diagnosing early-stage lung cancer with low-dose CT screening dramatically improves the long-term survival rate of cancer patients, a large-scale, 20-year international study shows.
Cancer has become strikingly more common in people under 50 in the past three decades, an international research team finds. The reseachers explore what this means for future death tolls.
While screening programs for several of the commonest cancers are now well established, lung cancer screening has yet to reach anywhere near the same proportion of at-risk patients.
A tiny robot which can travel deep into the lungs to detect and treat the first signs of cancer has been developed by researchers at the University of Leeds.
AI can use data from low-dose CT scans of the lungs to improve risk prediction for death from lung cancer, cardiovascular disease and other causes, a new study finds.
Assistance from an AI algorithm with high diagnostic accuracy improved radiologist performance in detecting lung cancers on chest X-rays and increased human acceptance of AI suggestions.
Unanswered questions are hampering clinicians in their efforts to get the best out of a precision medicine approach for their patients. Speaking at the Genomics and Precision Medicine Expo in London at the end of May, cancer educator Dr Elaine Vickers said the benefits of being matched to an investigational drug remain questionable for most people with advanced cancer.
Stereotactic body radiotherapy (SBRT) is increasingly used in early-stage lung cancer. However, experts caution that ditching surgical options in favour of "SBRT-only" has serious drawbacks.
A Korean research team successfully changed the properties of carcinogenic cells in the lungs and eliminate both drug resistance and their ability to proliferate out to other areas of the body.
This summer, The European Commission launched I3lung, a new research initiative as a part of Horizon Europe, the EU’s research and innovation program. This research initiative aims to create a cutting-edge, decision-making tool to help clinicians and patients select the best lung cancer treatment based on each patient’s specific needs and circumstances.
A new study led by researchers in Barcelona has determined the protein TIMP-1 as a valuable biomarker for the progression of lung adenocarcinoma. The results open the door to new treatments.
